Details:
Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for severe plaque psoriasis.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for severe plaque psoriasis.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for severe plaque psoriasis.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
BIMZELX (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
Analysis of pooled safety data from up to three years of treatment in Phase 2 and 3 clinical trials showed Bimzelx (bimekizumab) was generally well tolerated with no new safety signals identified over three years.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Key data to be presented on Bimzelx (bimekizumab) include new results from the BE BRIGHT open-label extension study evaluating maintenance of response with bimekizumab through three years in patients with moderate to severe plaque psoriasis who responded at week 16.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Pooled data from five Phase 3/3b trials showed that more than eight out of 10 patients who achieved complete skin clearance with bimekizumab at week 16, and entered open-label extension, maintained this response through two years.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2022
Details:
The approval in Japan is supported by the positive results from the Phase 3/3b clinical studies, which evaluated the efficacy and safety of bimekizumab compared with placebo, ustekinumab, adalimumab and secukinumab in adults with moderate to severe plaque psoriasis.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
New interim results from BE BRIGHT open-label extension study evaluating the long-term safety, tolerability and efficacy of bimekizumab in adult patients with plaque psoriasis. Bimekizumab is IL-17A and IL-17F inhibitor humanized IgG1 monoclonal antibody.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Bimzelx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021